Hepatitis C virus 3b strains in injection drug users in Guangdong Province, China, may have originated in Yunnan Province
The distribution of hepatitis C virus (HCV) genotypes/subtypes varies among different populations. Here, we investigated HCV infection and its genotype distribution in injection drug users (IDUs) in Guangdong Province of China. A total of 318 IDUs from two prisons were recruited. The genotypes/subtypes of HCV in IDUs were determined by phylogenetic analysis using E1 and/or NS5B gene sequences. Our previous data on blood donors (BDs) with no history of drug use were used as control population data for comparison. Our results showed that the prevalence of HCV 3b (20.9% vs. 3.6%, P = 3.4E-9) and 6a (57.0% vs. 39.8%, P = 1.2E-5) was higher in IDUs than in BDs. In contrast, the prevalence of HCV 1b (43.4% vs. 5.6%, P = 9.8E-23) in BDs was higher than in IDUs. Phylogeographic analysis indicated that HCV 3b migrated from Yunnan to Guangdong Province and became endemic, with further transmission to other regions of China. The trend of HCV 3b dissemination in China in IDUs requires further attention, and a strategy for prevention and therapy is needed.
This study was funded by a grant from the Weigao Fund of the Chinese Society of Blood Transfusion (No. CSBT-WG-2018-08), a grant from the National Natural Science Foundation of China (No. 81772208), and funding for the Key Medical Laboratory of Guangzhou from the Key Medical Disciplines and Specialties Program of Guangzhou, Guangdong, China.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Medical Ethics Committee of Guangzhou Blood Center.
All of the participants were duly informed about this study, and written informed consent was obtained from each participant.
- 2.Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, Zhou MG, Gong XH, Wang FZ, Zheng H, Luo HM, Bi SL, Wang N, Yang WZ, Liang XF (2011) A sero-epidemiological study on hepatitis C in China. Zhonghua liu xing bing xue za zhi 32:888–891Google Scholar
- 3.National Institutes of Health (2002) NIH consensus statement on management of hepatitis C: 2002. NIH Consen State Sci Statement 19:1–46Google Scholar
- 13.Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, Shabestari AN, Hassanpour G, Alavian SM, Asgari F (2012) Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 157:1959–1965CrossRefGoogle Scholar
- 23.Fu Y, Xia W, Wang Y, Tian L, Pybus OG, Lu L, Nelson K (2010) The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion 50:1505–1511CrossRefGoogle Scholar
- 27.Lu L, Wang M, Xia W, Tian L, Xu R, Li C, Wang J, Rong X, Xiong H, Huang K, Huang J, Nakano T, Bennett P, Zhang Y, Zhang L, Fu Y (2014) Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities. J Virol 88:7120–7129CrossRefGoogle Scholar
- 32.Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M, In CSG (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120CrossRefGoogle Scholar
- 38.Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, Study P, Study F (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:1867–1877CrossRefGoogle Scholar
- 40.Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB (2011) Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140(1182–1188):e1181Google Scholar
- 43.Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M (2013) High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 8:e80216CrossRefGoogle Scholar